Medtronic Inc. (NYSE: MDT) won CE Mark approval in the European Union for its new drug-eluting coronary stent system.
The Minneapolis-based medical device giant said the device’s new design gives it superior mobility within a patient’s vasculature.
Medtronic said the stent’s new “continuous sinusoid technology” gives the device significantly more deliverability than alternative stents when administered with the its MicroTrac delivery system.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Medtronic combined the cytostatic anti-proliferative drug zotarolimus and its biocompatible BioLinx polymer of its original Resolute drug-eluting stent with the continuous sinusoid technology to create the Resolute Integrity stent.
The Massachusetts Medical Devices Journal is the online journal of the medical devices industry in the Commonwealth and New England, providing day-to-day coverage of the devices that save lives, the people behind them, and the burgeoning trends and developments within the industry.
